First Author: Y.Park SOUTH KOREA
Co Author(s): S. Woo Y. Kim K. Park
Back to previous
To investigate long-term efficacy and safety of photodynamic therapy(PDT) on central serous chorioretinopathy(CSCR)
Retrospective single-centre case series
Patients who were treated with verteporfin PDT for CSCR in Seoul National University Bundang Hospital between March 2005 and March 2017 with a minimum follow-up of 36 months were reviewed. Patients previously treated with anti-VEGF injection for CSCR or having history of other chorioretinal disorders including choroidal neovascularization were excluded. Best-corrected visual acuities, central foveal thickness, subfoveal choroidal thickness, and photoreceptor recovery status were collected. Cox proportional hazard model was used for identifying risk factors for recurrence.
A total of 77 eyes of 74 patients were included. The mean age was 47.9 ± 7.3 (32.6 – 76.6) years and the mean follow-up duration was 57.3 ± 19.1 (36.1 – 129.3) months. 6 eyes(7.8%) underwent standard fluence PDT with standard dose, whereas 59 eyes underwent half-fluence PDT(76.7%) and 12 eyes (15.6%)underwent half-dose PDT. The mean visual improvement at the last follow-up was -0.17 ± 0.33 (-1.7 - 0.9, logMAR). In 6 eyes (7.8%), subretinal fluid was persistent until last follow-up date or until secondary treatment including re-PDT and anti-VEGF injection was done. In 14 eyes (18.2%), recurrence of subretinal fluid was detected. Cox regression analysis revealed no significant factor in reducing the risk of persistence and recurrence of subretinal fluid after PDT. 3 eyes(3.9%) developed choroidal neovascularization after PDT.
Verteporfin PDT for the treatment of CSCR showed good efficacy. Further study is needed for choroidal neovascularization after PDT, comparing the incidence with untreated controls.